Tracey Sacco
Corporate Officer/Principal chez SCHOLAR ROCK HOLDING CORPORATION
Fortune : 875 302 $ au 31/03/2024
Profil
Tracey Sacco is currently the Chief Commercial Officer at Scholar Rock Holding Corp.
Prior to this, she worked at Acceleron Pharma, Inc. as the SVP-Global Marketing & Alliance Management from 2012 to 2021.
She received her undergraduate degree from Boston College and her MBA from The Leonard N Stern School of Business.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 12/02/2024 | 49 285 ( 0,06% ) | 875 302 $ | 31/03/2024 |
Postes actifs de Tracey Sacco
| Sociétés | Poste | Début |
|---|---|---|
| SCHOLAR ROCK HOLDING CORPORATION | Corporate Officer/Principal | 06/02/2023 |
Anciens postes connus de Tracey Sacco
| Sociétés | Poste | Fin |
|---|---|---|
| ACCELERON PHARMA INC. | Sales & Marketing | 01/09/2021 |
Formation de Tracey Sacco
| Boston College | Undergraduate Degree |
| The Leonard N Stern School of Business | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| SCHOLAR ROCK HOLDING CORPORATION | Health Technology |
| Entreprise privées | 1 |
|---|---|
Acceleron Pharma, Inc.
 Acceleron Pharma, Inc. BiotechnologyHealth Technology Acceleron Pharma, Inc. is a biopharmaceutical company, which engages in the discovery, development and commercialization of therapeutics to treat serious and rare diseases. Its product candidates include Luspatercept, designed to patients with chronic anemia associated within a wide range of blood diseases; ACE-083, designed for the treatment of focal muscle disorders; and Sotatercept, designed to treat pulmonary arterial hypertension. The company was founded by John L. Knopf and Thomas P. Maniatis in June 2003 and is headquartered in Cambridge, MA. | Health Technology |
